Ruíz-Borrego, Manuel
Guerrero-Zotano, Angel
Bermejo, Begoña
Ramos, Manuel
Cruz, Josefina
Baena-Cañada, Jose Manuel
Cirauqui, Beatriz
Rodríguez-Lescure, Álvaro
Alba, Emilio
Martínez-Jáñez, Noelia
Muñoz, Montserrat
Antolín, Silvia
Álvarez, Isabel
Del Barco, Sonia
Sevillano, Elena
Chacón, José Ignacio
Antón, Antonio
Escudero, María José
Ruiz, Victoria
Carrasco, Eva
Martín, Miguel http://orcid.org/0000-0001-9237-3231
Seguí, M. A.
Ayala, F.
de la Haba, J.
Martínez, P.
González, S.
Lahuerta, A.
Toral, J. C.
de Dueñas, E. Martínez
Florián, J.
Godes, M. J.
Llorca, C.
Blancas, I.
Jara, C.
Morales, S.
Arcusa, A.
Martínez, A.
Vicente, E.
de Juan, A.
Rodríguez, M.
García, M.
García, P.
Bayo, J. L.
Carañana, V.
Casinello, J.
Jolis, L.
Gil, M.
Cañabate, C.
Oltra, A.
Ramírez, J.
Lomas, M.
Barnadas, A.
Sureda, M.
Carabantes, F.
Moreno, I.
Moreno, A. L.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
https://doi.org/10.1007/s10549-019-05296-8
Funding for this research was provided by:
AstraZeneca Farmaceutica Spain
Article History
Received: 4 February 2019
Accepted: 24 May 2019
First Online: 31 May 2019
Compliance with ethical standards
:
: B Bermejo her institution has received research funding from AstraZeneca, Merck, Roche Pharma AG, Boehringer Ingelheim, Novartis and Roche outside the current trial. M. Ramos has participated in advisory boards of AstraZeneca, Roche, Novartis and Pfizer and received speaker honoraria from AstraZeneca, Roche, Novartis and Pfizer. J. Cruz has participated in advisory boards of AstraZeneca, Roche, Novartis, Pharmamar, Eisai, Lilly, Celgene, Astellas, Amgen, Glaxo, and Pfizer and received speaker honoraria from Glaxo, AstraZeneca, Roche, Novartis, Pharmamar, Eisai, Lilly, Celgene, Astellas, Amgen, and Pfizer. J.M. Baena-Cañada has participated in advisory boards of AstraZeneca, Roche, Novartis, Amgen, Bristol, Eisay, Celgene and Pfizer and received speaker honoraria from Roche and Ferrer. His institution has received research funding from AstraZeneca. B. Cirauqui has received speaker honoraria and funding for some independent medical education activities from Astra Zeneca outside de current trial. A Rodríguez-Lescure has participated in advisory boards of Roche, Novartis, MSD and Pfizer and has received speaker honoraria from AstraZeneca, Roche, Novartis, Kern Pharma, Amgen, and Pfizer; his institution has received research funding from Novartis, Pfizer, Lilly and Roche outside the current trial. E. Alba has participated in advisory boards of Roche, Pfizer, Novartis and Lilly, his institution has received funding from Roche and Sysmex. N. Martínez Jañez has participated in advisory boards of AstraZeneca, Roche, Novartis, Celgene, Eisai, and Pfizer and received speaker honoraria from Roche, Novartis, Eisai and Pfizer. M. Muñoz: has participated in advisory boards of AstraZeneca, Merck and Novartis and expert opinion of Roche. She has received scientific meetings travel expenses from AstraZeneca and Roche. I. Álvarez López has participated in consultant or advisory boards of AstraZeneca, Pfizer, Palex, Roche, Novartis and received speaker honoraria from AstraZeneca, Pfizer, Roche, Eisai, received scientific meetings travel expenses from Pfizer and Roche. Her institution has received research funding from AstraZeneca, Pfizer, Roche, Novartis outside the current trial. A. Antón: has participated in consultant or advisory boards of Bayer. Him institution has received research funding from Roche outside the current trial. E. Carrasco´s immediate family member has participated in advisory boards of Pfizer and received speaker honoraria form Pfizer and his institution has received research funding from Pfizer. M. Martin has participated in advisory boards of AstraZeneca, Roche, Novartis, Pharmamar, Amgen, and Pfizer and received speaker honoraria from Glaxo, AstraZeneca, Roche, Novartis, Amgen, and Pfizer; his institution has received research funding from Novartis and Roche outside the current trial. E. Sevillano has received speaker honorary from Roche, Eisai, MSD and Ipsen. GEICAM has received funding from AstraZeneca for some independent medical education activities and research projects performed by the Group in which all authors collaborated. Rest of authors declare no conflict of interest.
: The study was performed in accordance with the Declaration of Helsinki, approved by the institutions’ ethical committees and health authorities in Spain, and registered at EUDRACT (2007-003417-14) and ClinicalTrials.gov (NCT00543127). Written informed consent was obtained from all patients before performing any protocol specific procedure.